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Available online 28 March 2019Background: The underlying mechanisms causing myocardial ischemia in non-obstructive coronary artery dis-
ease (CAD) are still unclear. We explored whether left ventricular hypertrophy (LVH) was associated with myo-
cardial ischemia in patients with stable angina and non-obstructive CAD.
Methods: 132 patients (mean age 63 ± 8 years, 56% women) with stable angina and non-obstructive CAD diag-
nosed as b50% stenosis by coronary computed tomography angiography (CCTA) underwent myocardial contrast
stress echocardiography. Left ventricular (LV) hypertrophy (LVH)was identifiedby LVmass index N46.7 g/m2.7 in
women and N49.2 g/m2.7 inmen. Patientswere grouped according to presence or absence ofmyocardial ischemia
by myocardial contrast stress echocardiography. The number of LV segments with ischemia at peak stress was
taken as a measure of the extent of myocardial ischemia.
Results:Myocardial ischemia was found in 52% of patients, with on average 5 ± 3 ischemic LV segments per pa-
tient. The group with myocardial ischemia had higher prevalence of LVH (23 vs. 10%, p = 0.035), while age, sex
and prevalence of hypertension did not differ between groups (all p N 0.05). Inmultivariable regression analyses,
LVH was associated with presence of myocardial ischemia (odds ratio 3.27, 95% confidence interval [1.11–9.60],
p= 0.031), and larger extent ofmyocardial ischemia (β=0.22, p=0.012), independent of confounders includ-
ing age, hypertension, obesity, hypercholesterolemia, calcium score and segment involvement score by CCTA.
Conclusions: LVH was independently associated with both presence and extent of myocardial ischemia in pa-
tients with stable angina and non-obstructive CAD by CCTA. These results suggest LVH as an independent con-
tributor to myocardial ischemia in non-obstructive CAD.
Clinical trial registration number: ClinicalTrials.gov, identifier NCT018535271.
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Management of patients with non-obstructive coronary artery dis-
ease (CAD) and stable angina represents a major clinical challenge
[1,2]. Non-obstructive CAD is a common finding, in particularly among
women [3,4]. During recent years it has been well documented that pa-
tients with non-obstructive CAD have increased cardiovascular morbid-
ity and mortality, contrasting the original conception that it was a
benign condition [2–6]. Myocardial ischemia is characterized by a
mismatch between the myocardial oxygen supply and demand, and
has adverse prognostic implications in patients with CAD [7]. Further,
detection of myocardial ischemia in non-obstructive CAD may help to
identify the patients with increased risk of impaired prognosis [8]..
eliability and freedom from biasMoreover, the pathophysiologic mechanisms leading to myocardial
ischemia in patients with non-obstructive CAD appear to bemultifacto-
rial. Several factors, including hypertension, atherosclerosis and micro-
vascular dysfunction, have been reported as potential contributors to
myocardial ischemia [1,9,10]. However, the underlying disease mecha-
nisms contributing to myocardial ischemia in the individual patient
may often not be identified during routine diagnostic work-up, and ev-
idence based guidelines for personalized management of patients with
non-obstructive CAD are still missing [1].
Left ventricular hypertrophy (LVH) is the hallmark of hypertension
mediated organ damage and is an independent predictor of both all-
cause mortality and cardiovascular morbidity in general and hyperten-
sive population [11–14]. In hypertensive patients, LVH, in particular the
concentric type, has been associated with presence of symptomatic
myocardial ischemia even with normal coronary angiography [15]. It
has previously been suggested that hypertensive patients with LVH
have a lower threshold for myocardial ischemia and that this may ex-
plain the increased cardiovascular risk [16]. However, the impact of
2 I. Eskerud et al. / International Journal of Cardiology 286 (2019) 1–6LVH, a potential treatment target, on myocardial ischemia in patients
with non-obstructive CAD has not previously been explored. Thus, the
aim of this studywas to assesswhether presence of LVHmay contribute




The Myocardial Ischemia in Non-obstructive Coronary Artery
Disease (MicroCAD) study is a cross-sectional study that prospec-
tively included patients referred to coronary computed tomography
angiography (CCTA) at Department of Heart Disease, Haukeland
University Hospital, Bergen, Norway in the period May 2013 until
November 2014 by experienced cardiologist on a clinical suspicion
of stable angina and that were diagnosed with non-obstructive
CAD. Other inclusion criteria were age N30 years, clinical stable an-
gina, defined as exercise induced angina pectoris and/or dyspnea
for at least 6 months, and at least one cardiovascular risk factor (hy-
pertension, hypercholesterolemia, diabetes, smoking or family his-
tory of premature CAD). Exclusion criteria were clinically unstable
angina, severe valve disease, mechanical valve prosthesis, arrhyth-
mias, severe pulmonary disease and known allergies to ultrasound
contrast.
In total 153 patients were identified and invited, of whom 21 de-
clined participation, leaving 132 patients included in the MicroCAD
study. All participants signed informed consent. The MicroCAD project
was approved by the regional ethical committee andwas performed ac-
cording to the 1975 Declaration of Helsinki. The MicroCAD project is
registered at ClinicalTrials.gov with identifier NCT01853527.
2.2. Cardiovascular risk factors and symptoms
The patients reported cardiovascular risk factors, medical history and
use of medication on a standardized questionnaire. Family history of pre-
mature CADwas considered present if documented CADwas present in a
first-degree relative before the age of 65 years in women and 55 years in
men. Hypercholesterolemia was defined as total serum cholesterol
N6.5 mmol/l or use of cholesterol-lowering treatment. Body mass index
(BMI) was calculated as body weight in kilograms divided by height in
meters squared. Obesity was defined as BMI ≥30 kg/m2. Hypertension
was defined as known hypertension, use of antihypertensive drugs
or high blood pressure at the clinic visit (systolic blood pressure
≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg) [17].
Fasting blood samples were collected to measure serum lipid profile,
serum glucose and creatinine. Glomerular filtration rate was esti-
mated by the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) formula [18].
2.3. Conventional echocardiography
Echocardiographywas performed following a standardized protocol
and interpreted in linewith current joint guidelines of the American So-
ciety of Echocardiography and the European Association of Cardiovas-
cular Imaging [19]. We interpreted the images offline at the Bergen
Echocardiography Core Laboratory blinded to clinical data. All images
were proof-read by the same experienced reader (MTL). Left ventricular
(LV) mass was calculated by Devereux's equation and indexed for
height in meters in the allometric power of 2.7. We defined LVH by
the prognostically validated sex specific cut-off values of LV mass
index (LVMi) N46.7 g/m2.7 in women and N49.2 g/m2.7 in men [12,20].
LV ejection fraction was calculated by Simpson's biplane method. Rela-
tive wall thickness was calculated as posterior wall thickness/LV inter-
nal radius ratio and considered increased if ≥0.43 [19]. LV geometry
was classified into four groups based on the presence of LVH and normalor increased relative wall thickness [19]. Accordingly, normal LV geom-
etrywas defined as no LVHandnormal relativewall thickness, concentric
remodeling as no LVH and increased relative wall thickness, concentric
LVH as LVH and increased relative wall thickness, and eccentric LVH as
LVH and normal relative wall thickness [19].2.4. Myocardial contrast echocardiography for myocardial perfusion
Myocardial contrast echocardiography was performed using
real-time low-mechanical index imaging and destruction replen-
ishment following current guidelines [21]. Ultrasound contrast
agent (SonoVue, Bracco, Milan, Italy) was given intravenously as
1 ml bolus followed by 1 ml/h infusion with a rotating infusion
pump (VueJet, Bracco, Milan, Italy). Apical 2-, 3- and 4-chamber
views were used to score wall motion and myocardial perfusion at
rest and at peak dobutamine stress, defined as 85% of maximum
age predicted (200 – age) heart rate during stress echocardiography
[21]. Wall motion was scored visually as normal or abnormal, and
myocardial perfusion as normal or delayed in the individual 17-
segments of the LV. Stress induced myocardial ischemia was de-
fined as presence of delayed contrast replenishment 2 heart beats
after flash at peak stress in any LV segment. The number of LV seg-
ments with delayed perfusion at peak stress was taken as a measure
of the extent of myocardial ischemia.2.5. Coronary computed tomography angiography and non-obstructive
coronary artery disease
CCTA was performed by a 256-slice dual source scanner (Somatom
Definition Flash, Siemens, Germany) with electrocardiographic (ECG)
-triggered acquisitions. Patients with heart rate N60 beats per minute
were given metoprolol intravenously (1 mg/ml, maximum 20 mg)
until heart rate was ≤60 beats per minute. The patients received non-
ionic contrast intravenously as 80–115 ml iomeprol 400 mg I/ml
(Iomeron®, Bracco, Milan, Italy) according to body weight. All patients
received 0.4 mg sublingual nitroglycerin in order to optimize image
quality. Experienced readers analyzed all images for detection of coro-
nary artery stenosis using amodified 20-segment American Heart Asso-
ciation model [22]. Non-obstructive CAD was defined as presence of ≥
one stenosis with lumen diameter reduction 1–49% in any coronary ar-
tery segment. CCTAwas revised in all patients where we detectedmyo-
cardial ischemia in order to confirm diagnosis of non-obstructive CAD.
Segment involvement score was calculated as the total number of coro-
nary segments with atherosclerotic plaque [23].2.6. Statistical analysis
Data analysis was performed using IBM SPSS Statistics version 24
(IBM Corporation, Armonk, NY, USA). The sample size was determined
in order to have 80% power with statistical level of 0.05 to find 50% dif-
ferences in prevalence of LVH between patients with and without myo-
cardial ischemia, including an anticipated dropout rate of 5%. The study
population was grouped into patients with and without myocardial is-
chemia. We compared groups by unpaired Student's t-test for continu-
ous variables and Chi-Square test for categorical variables. The results
are presented as mean ± standard deviation or median and interquar-
tile range for continuous variables and number and percentages for cat-
egorical variables. Predictors of myocardial ischemia were assessed in
uni- and multivariable logistic regression models and reported as odds
ratio (OR) with 95% confidence intervals (CI). Independent covariables
of the extent of myocardial ischemia were identified by uni- andmulti-
variable linear regression analysis with standardized coefficients (β). A
p b 0.05 was considered significant in all analyses.
Table 1
Clinical characteristics of the total study population and of groups of patients with and without myocardial ischemia.
Total (n = 132) Ischemia (n = 69) No ischemia (n = 63) p
Age (years) 63 ± 8 63 ± 9 62 ± 8 0.317
Female sex (%) 56 54 59 0.555
BMI (kg/m2) 27.7 ± 4.5 27.2 ± 4.1 28.2 ± 4.8 0.206
Obesity (%) 24 16 32 0.032
Hypertension (%) 75 81 68 0.077
Diabetes (%) 13 12 13 0.919
Current cigarette smoking (%) 16 13 19 0.341
Family history of premature CAD (%) 64 58 70 0.192
Hypercholesterolemia (%) 48 54 41 0.156
Systolic blood pressure (mm Hg) 135 ± 16 135 ± 17 135 ± 16 0.795
Diastolic blood pressure (mm Hg) 79 ± 13 79 ± 13 79 ± 13 0.998
Heart rate (bpm) 69 ± 12 71 ± 13 68 ± 12 0.303
Serum glucose (mmol/L) 5.9 ± 1.6 5.9 ± 1.0 6.0 ± 2.0 0.727
Estimated GFR (mL/min/1.73 m2) 86 ± 14 87 ± 15 85 ± 13 0.389
Total serum cholesterol (mmol/L) 5.0 ± 1.3 5.1 ± 1.4 5.0 ± 1.2 0.719
Serum HDL cholesterol (mmol/L) 1.5 ± 0.4 1.5 ± 0.5 1.5 ± 0.4 0.896
Serum LDL cholesterol (mmol/L) 3.2 ± 1.2 3.3 ± 1.3 3.2 ± 1.0 0.718
Serum triglycerides (mmol/L) 1.47 ± 0.96 1.55 ± 0.84 1.39 ± 1.08 0.340
Acetylsalicylic acid (%) 47 57 36 0.026
Statin (%) 38 40 36 0.627
Antihypertensive treatment (%) 58 59 56 0.729
Beta blocker (%) 30 23 36 0.126
Calcium channel blocker (%) 18 24 12 0.094
LV internal diastolic dimension (mm) 45.2 ± 5.5 45.0 ± 5.5 45.3 ± 5.5 0.764
LV internal systolic dimension (mm) 29.2 ± 5.3 29.0 ± 5.4 29.4 ± 5.2 0.678
Septal thickness (mm) 11.8 ± 2.0 12.3 ± 2.1 11.3 ± 1.8 0.003
Posterior wall thickness (mm) 9.3 ± 1.9 9.4 ± 2.1 9.1 ± 1.6 0.476
LV ejection fraction (%) 62 ± 7 63 ± 6 60 ± 7 0.019
LVMi (g/m2.7) 40.1 ± 9.3 42.1 ± 9.7 37.9 ± 8.4 0.009
LVH (%) 17 23 10 0.035
Relative wall thickness 0.42 ± 0.11 0.42 ± 0.11 0.41 ± 0.10 0.487
Calcium score (HU) 42(14–107) 47(16–127) 37(11–83) 0.264
Number of diseased coronary arteries 1.6 ± 1.8 1.7 ± 0.8 1.5 ± 0.7 0.084
Multi-vessel disease (%) 54 60 48 0.168
Segment involvement score 2.6 ± 1.6 2.8 ± 1.8 2.4 ± 1.3 0.149
BMI, bodymass index; CAD, coronary artery disease; bpm, beats per minute; GFR, glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LV, left ventric-
ular; LVMi, left ventricular mass index; LVH, left ventricular hypertrophy; HU, Hounsfield units.
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3.1. Clinical characteristics and myocardial contrast stress echocardiography
All 132 study participants had symptomatic stable angina. Prior
stress testing with exercise ECGwas performed in 115 (89%) of the par-
ticipants, and a total of 79 (67%) of the testswere reported to be negative
or inconclusive due to low exercise capacity or left bundle branch block,
leaving 36 patients (31%) with a positive exercise ECG. MyocardialFig. 1. Left ventricular geometry in patients with and without myocardial ischemiaischemia by contrast stress echocardiography was found in 69 patients
(52%), and among patients with a positive exercise ECG, 67% were diag-
nosed with myocardial ischemia by contrast stress echocardiography.
The median time from CCTA to myocardial contrast echocardiography
was 133 days (interquartile range 98–188 days). The group with myo-
cardial ischemia had a 2-fold higher prevalence of LVH (Table 1), in par-
ticularly concentric LVH (Fig. 1). The groups did not differ in age, sex,
prevalence of hypertension or antihypertensive treatment, however obe-
sity was less common in the group with myocardial ischemia (Table 1).. Figure legend: LVH, Left ventricular hypertrophy. *p b 0.05 between groups.
Table 2
Covariables of myocardial ischemia identified in logistic regression analyses.
Variable Univariable analysis Multivariable analysis
OR 95% CI p OR 95% CI p
LVH 2.87 1.04–7.88 0.041 3.19 1.04–9.76 0.043
Age (years) 1.02 0.98–1.06 0.315 0.99 0.94–1.04 0.623
Hypertension 2.05 0.92–4.59 0.080 2.24 0.97–5.65 0.059
Obesity 0.41 0.18–0.94 0.035 0.38 0.15–1.00 0.049
Hypercholesterolemia 1.65 0.83–3.28 0.157 1.98 0.92–4.28 0.083
Calcium score 1.00 0.99–1.01 0.461 1.00 0.99–1.01 0.874
Segment involvement score 1.18 0.94–1.49 0.159 1.19 0.87–1.65 0.280
Female sex 0.81 0.41–1.62 0.555
Diabetes 0.95 0.33–2.70 0.919
Current smoking 0.62 0.23–1.67 0.344
OR, odds ratio; CI, confidence interval; LVH, left ventricular hypertrophy.
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reflecting extent and severity of non-obstructive CAD, did not differ be-
tween the groups (Table 1).
By myocardial contrast stress echocardiography, 89% of patients
reached age predicted maximal heart rate at peak stress. Nine of the 14
patients (65%) with lower than predicted maximal heart rate at peak
stress hadmyocardial ischemia. Patients with andwithout myocardial is-
chemia had similar peak systolic blood pressure and heart rate (121±23
vs. 123 ± 22 mm Hg, p = 0.616 and 132 ± 10 vs. 132 ± 11 beats per
minute, p = 0.846). Fifteen patients (11%) had abnormal wall motion at
peak stress. In 11 of these 15 patients wall motion abnormality was in
the region supplied by the left anterior descending artery. The average ex-
tent of stress induced myocardial ischemia was 5 ± 3 LV segments. Wall
motion abnormalities were significantly correlatedwith perfusion abnor-
malities during stress echocardiography, inwhich13 (87%) of the patients
with wall motion abnormalities also had perfusion abnormalities (p =
0.006). However, most patientswith perfusion abnormalities had no con-
comitant wall motion abnormalities.3.2. Covariates of myocardial ischemia
In univariable logistic regression analysis, myocardial ischemia was
associated with presence of LVH and absence of obesity (Table 2). Myo-
cardial ischemia remained independently associated with presence of
LVH inmultivariable analysis even after adjusting for age, hypertension,
obesity, hypercholesterolemia, calcium score and SIS (Table 2).
In univariable linear regression analyses, larger extent of myocardial is-
chemiawas associatedwith presence of LVH, hypertension andhypercholes-
terolemia(Table3). Inmultivariable linear regressionanalysis, largerextentof
myocardial ischemia remained associated with LVH independent of hyper-
tension, obesity, hypercholesterolemia, calcium score and SIS (Table 3).Table 3






β p β p
LVH 0.19 0.034 0.23 0.010
Age (years) 0.002 0.984 −0.18 0.056
Hypertension 0.20 0.021 0.25 0.005
Obesity −0.16 0.069 −0.18 0.044
Hypercholesterolemia 0.18 0.039 0.24 0.006
Calcium score 0.09 0.329 0.12 0.233
Segment involvement score 0.12 0.176 0.06 0.519
Female sex −0.11 0.191
Diabetes 0.09 0.325
Current smoking −0.09 0.335
Multiple R2 = 0.18, p = 0.001.
LVH, left ventricular hypertrophy.4. Discussion
4.1. Myocardial ischemia and non-obstructive CAD
The present study demonstrates that about 50% of patients with sta-
ble angina and non-obstructive CAD have myocardial ischemia that can
be detected by myocardial contrast stress echocardiography. The pres-
ent results add to current knowledge by identifying the association of
LVHwith presence and extent of myocardial ischemia in these patients,
independent of presence of hypertension.
Traditionally, myocardial ischemia has been perceived as secondary
to coronary artery disease which directly obstructs blood flow to the
myocardium [9,24]. However, we and others have previously demon-
strated that myocardial ischemia may be present also in non-
obstructive CAD [8,15,25]. The association between myocardial ische-
mia and LVH iswell known as one of several mechanisms thatmay con-
tribute to myocardial ischemia in patients with non-obstructive CAD, in
addition to coronary vasospasm, coronary microvascular and endothe-
lial dysfunction [1,10,26]. For instance, subendocardial ischemia and re-
duced myocardial blood flow have been detected by single photon
computed tomography and positron emission tomography in patients
with hypertrophic cardiomyopathy and in diabetes patients with LVH
[27–29]. Reversible and irreversible ischemia was also detected in 35%
of patients with LVH and exercise induced ST-depression, and was par-
ticularly prevalent in patients with concomitant CAD [30]. Further, in
linewith our results, it has previously been reported that LVHmay con-
tribute to lower the ischemic threshold in patients with hypertension
and clinical evidence of CAD [31].
In animal studies, LVH has been suggested to contribute to myocar-
dial ischemia through several mechanisms, such as reduced myocardial
capillary density, increased LVfilling pressure and increasedmyocardial
oxygen demand [32,33]. In patientswith ST elevationmyocardial infarc-
tion, presence of LVH has been associated with higher incidence of mi-
crovascular obstruction as well as larger myocardial infarct size by
cardiac magnetic resonance imaging [34]. The present results add to
this by demonstrating that LVH may contribute to myocardial ischemia
also in patients with stable angina and non-obstructive CAD.
As demonstrated, presence of hypertensionwas associatedwith larger
extent ofmyocardial ischemia independent of LVH in our study. This sug-
gests that hypertension contributes to myocardial ischemia through sev-
eral mechanisms beyond the higher LV mass. As recently pointed out by
Bairey Merz et al., hypertension may also influence myocardial perfusion
in non-obstructive CAD through impaired vasomotion, endothelial dys-
function, atherosclerosis, reduced coronary microvascular density and
thickened and stiffened microvessels with poor autoregulatory capacity
[1].
In addition to LVH and hypertension, absence of obesity and pres-
ence of hypercholesterolemia were associated with a larger extent of
myocardial ischemia in our study. The inverse association between obe-
sity and myocardial ischemia was unexpected, and could not be ex-
plained by group-differences in sex or smoking. On the other hand,
elevated total cholesterol is a well-established risk factor of CAD [35].
Furthermore, myocardial ischemia was not detected in all patients
with LVH, suggesting that the etiology ofmyocardial ischemia wasmul-
tifactorial also in our study.
Although the present study is small, our results may have potential
important clinical implications for management of patients with non-
obstructive CAD and stable angina. Current guidelines for management
of patients with stable angina have pointed out the need for scientifi-
cally based management of non-obstructive CAD [36]. In particular,
echocardiographic detection of LVH and myocardial ischemia may
offer targets for a more personalized management of patients with
non-obstructive CAD, pointing to the value of multimodality imaging
in these patients. Moreover, antihypertensive treatment is associated
with normalization of LV geometry and improved prognosis [11,37].
Our results also emphasize the importance of cardiovascular risk
5I. Eskerud et al. / International Journal of Cardiology 286 (2019) 1–6control. In line with this, it has recently been demonstrated that in pa-
tients with non-obstructive CAD and myocardial infarction, the risk of
new major cardiovascular events is predicted by established cardiovas-
cular risk factors, including hypertension, diabetes and smoking [38].
Further, patients with non-obstructive CAD less often receive secondary
preventivemedication aftermyocardial infarction [39]. Accordingly, op-
timal medical treatment of non-obstructive CAD should be verified in
prospective clinical studies.
4.2. Study limitations
We have selected a population with high risk of cardiovascular
disease and our results cannot necessarily be generalized to a general
angina population. The cross-sectional study design precludes iden-
tification of any causal relation between LVH and myocardial ische-
mia. The proportion of women was lower than what could be
expected [40]. This might be explained by a referral bias, as only pa-
tients referred to CCTA by a cardiologist due to suspected CAD were
eligible for inclusion. It is well documented from the Coronary CT An-
giography Evaluation for Clinical Outcomes: An International Multi-
center (CONFIRM) registry that women referred to CCTA have a
higher pre-test probability of CAD then men [41]. In addition, the
small study size did not allow stratification of the results by sex due to
insufficient statistical power. However, our study population reflects a
large group of patients in clinical practice who currently lack evidence-
based guidelines for diagnostic work-up and management.
5. Conclusion
In patients with stable angina and non-obstructive CAD on CCTA,
myocardial ischemia was found in half of the patients and was inde-
pendently associated with presence of LVH. Our results suggest LVH
as a potential treatment target in patients with stable angina and
non-obstructive CAD to be explored in further clinical studies.
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